Compare · ACAD vs JNJ
ACAD vs JNJ
Side-by-side comparison of ACADIA Pharmaceuticals Inc. (ACAD) and Johnson & Johnson (JNJ): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ACAD and JNJ operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- JNJ is the larger of the two at $609.12B, about 139.0x ACAD ($4.38B).
- Over the past year, ACAD is up 13.4% and JNJ is up 54.6% - JNJ leads by 41.2 points.
- JNJ has been more active in the news (10 items in the past 4 weeks vs 4 for ACAD).
- Both have 25 recent analyst ratings on file.
- Company
- ACADIA Pharmaceuticals Inc.
- Johnson & Johnson
- Price
- -
- -
- Market cap
- $4.38B
- $609.12B
- 1M return
- +22.38%
- +7.55%
- 1Y return
- +13.35%
- +54.56%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 1985
- News (4w)
- 4
- 10
- Recent ratings
- 25
- 25
ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; Trofinetide, a novel synthetic analog for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor for treating cognition and schizophrenia. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Latest ACAD
- Acadia Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 4, 2026
- Acadia Pharmaceuticals Appoints Carl Segerstrom as Chief People Officer
- PRINCIPAL ACCOUNTING OFFICER Kihara James sold $297,912 worth of shares (11,421 units at $26.08) as part of a pre-agreed trading plan, decreasing direct ownership by 47% to 13,088 units (SEC Form 4)
- DAYBU® (trofinetide) Recommended for Approval in the European Union by CHMP
- SEC Form S-8 filed by ACADIA Pharmaceuticals Inc.
- Director Baker Bros. Advisors Lp was granted 37,244 shares (SEC Form 4)
- Director Harrigan Edmund converted options into 8,107 shares, increasing direct ownership by 23% to 43,148 units (SEC Form 4)
- Director Ndu Adora converted options into 8,107 shares, increasing direct ownership by 33% to 32,908 units (SEC Form 4)
- Director Daly James M converted options into 8,107 shares, increasing direct ownership by 201% to 12,148 units (SEC Form 4)
- Director Brege Laura converted options into 8,107 shares, increasing direct ownership by 54% to 23,202 units (SEC Form 4)
Latest JNJ
- Johnson & Johnson Announces Collaboration with TIME to Introduce New Healthcare Champion of the Year Award
- DePuy Synthes Acquires Expanding Innovations™
- Johnson & Johnson filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2026
- Johnson & Johnson reports Q2 2026 results, raises 2026 outlook
- Johnson & Johnson Announces FDA Approval for the Dual Energy THERMOCOOL SMARTTOUCH SF Platform
- Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity
- Johnson & Johnson presents new IMAAVY® (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis
- SEC Form 11-K filed by Johnson & Johnson
- SEC Form 11-K filed by Johnson & Johnson